The authors advised clinicians to carefully consider which antipsychotics they prescribe their patients with metabolic dysfunction, as some are known to be diabetogenic.
These data may be useful to clinicians in considering the risks and benefits of prescribing haloperidol for patients with cardiac morbidity.
In patients with a history of pre-diagnostic violence, a history of non-violent offending in the 18-month period pre-diagnosis was the strongest predictor of future violence.
Major depressive disorder with psychotic features had comparative long-term outcomes with schizophrenia, schizoaffective disorder, and bipolar disorder.
The authors pointed to a possible difference in the specific symptoms alleviated by different types of stimulation.
The early sustained recovery group was more likely to have a diagnosis other than schizophrenia, particularly mania or brief psychosis.
"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.
Although various clinical and psychosocial factors were associated with unhealthy lifestyle factors and higher risk for CVD, the strongest associations were with negative symptoms.
Ketamine-dependent patients who exhibited psychosis demonstrated levels of spatial problem solving and verbal memory impairment similar to those of patients with schizophrenia.
Treatment beyond antipsychotic drugs is needed for people with schizophrenia, as positive symptoms are a peripheral node in the network.
Despite the recognition that early daily tobacco use likely increases the risk for later psychosis, investigation of the effect of covariates such as substance use, existing psychotic features, or parental/family factors was lacking in the literature.
These results suggest that CBT alone may be insufficient in enhancing work outcomes in patients with schizophrenia, despite its efficacy in treating other symptoms.
The meta-analysis showed raloxifene to be effective for positive symptoms, negative symptoms, and general psychopathology, with greatly homogeneous results.
The findings of this meta-analysis suggested that both repetitive transcranial magnetic stimulation and transcranial direct current stimulation were significantly more effective at improving negative symptoms than sham stimulation.
Investigators determined infections in the first year of life to be the "sensitive period" for risk of adult nonaffective psychosis.
Bipolar disorder (31.9%), depression (19.8%), schizophrenia (14.2%), and anxiety disorders (9.1%) were the most common mental health issues reported. Approximately 13% of evacuees with a mental health concern reported a history of post-traumatic stress disorder.
Children who are involved in sibling bullying are at a higher risk of developing a psychotic disorder.
Investigators selected 15 genes associated with schizophrenia due to high expression in both brain tissue and B-lymphocyte cells.
There has been a question of whether antipsychotic medications are truly acting upon "primary" negative symptoms, or whether they are instead improving "secondary" negative symptoms via improvement in positive or depressive symptoms.
Although all-cause pharmacy costs were higher in the paliperidone palmitate group, adjusted all-cause medical costs were lower.
Use of virtual reality environments in which participants interact with computer-controlled situations or avatars enables a more fine-tuned approach to exposure in the context of cognitive behavioral therapy.
A combination of an SSRI and antipsychotics in a clinical setting most likely does not lead to a further deterioration of metabolic variables to a clinically significant degree.
Investigators seek the association between psychosis and complication risk after total joint arthroplasty.
P50 processing may inform researchers in the future development of interventions targeting cognitive impairment in schizophrenia.
All patients with a substance-induced psychosis should be offered follow-up.
This research suggests that interventions to improve cognitive insight may bolster neurocognition in schizophrenia.
Twelve antipsychotics, including olanzapine, ziprasidone, and lurasidone, were examined in a meta-analysis.
Antidepressants may effectively treat depression in patients with comorbid schizophrenia.
Abstinence-contingent incentives improved smoking cessation outcomes among economically disadvantaged smokers with mental illness.
A growing body of research consistently shows that patients with schizophrenia often suffer from sleep disturbances.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Clinician Insight: Exploring the Link Between Bipolar Disorder and Binge Eating Disorder
- #MeToo: Helping Victims Cope With Sexual Harassment
- Association Between Psychosis and Development of Dementia in Older Men
- Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids
- Personality Functioning Associated With Global Functioning in Bipolar Disorder I
- Nutritional Influences on Bipolar Disorder in Children
- Triiodothyronine in the Treatment of Bipolar Depression
- Old Challenges and New Directions in Managing Tardive Dyskinesia
- Similar Rates of Childhood Trauma in Schizophrenia and Substance Use Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Childhood Insulin Resistance Associated With Later Psychosis
- Lamotrigine Similar to Placebo in Treating Borderline Personality Disorder
- Glucocorticoids May Increase Risk of Developing Schizophrenia Spectrum Disorder
- Predictors, Incidence of Long-term Use of Benzodiazepines, Z-Drugs in Bipolar Disorder
- Cardiometabolic Dysregulation Associated With Cognitive Decline Mediated by Depression